Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis

OBJECTIVE: Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered intravenously or subcutaneously with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to be superior to csDMARDs alone for improving rheumatoid arthritis (RA) disease activity. This study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:RMD Open
Autors principals: Strand, Vibeke, Michalska, Margaret, Birchwood, Christine, Pei, Jinglan, Tuckwell, Katie, Finch, Rebecca, Kivitz, Alan J, Smolen, Josef S, Burmester, Gerd R
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2018
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018870/
https://ncbi.nlm.nih.gov/pubmed/29955380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000602
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars